HOME >> BIOLOGY >> NEWS
Over the edge: New therapeutic strategy takes advantage of stressed cancer cells

A biochemical alteration that has long been viewed as an adverse aspect of tumor biology may turn out to be a deadly double-edged sword for the cancer cells themselves. Scientists have successfully exploited the oxidative stress common in cancer cells to preferentially kill malignant cells. This approach has the therapeutic advantage of selectively targeting cancer cells while exhibiting minimal toxicity in normal cells. The research is published in the September 2006 issue of the journal Cancer Cell, published by Cell Press.

Most cancer cells exhibit overproduction of reactive oxygen species (ROS), which is thought to provide favorable conditions for cancer cell growth, genetic instability, and survival. Dr. Peng Huang from the Department of Molecular Pathology at the University of Texas M.D. Anderson Cancer Center and colleagues hypothesized that increased ROS generation may also make cancer cells highly vulnerable to exogenous ROS-modulating agents that would not be toxic to normal cells with low ROS output.

The researchers examined the ability of a naturally occurring compound called -phenylethyl isothiocyanate (PEITC), which is known to modulate cellular antioxidant pathways, to push cancer cells to even higher ROS levels that result in cell death. Oncogenically transformed cells exhibited high basal ROS levels and were more sensitive to PEITC than nontransformed cells. PEITC interfered with a specific antioxidant system that the cancer cells relied on to maintain a ROS balance that was compatible with survival. Treatment with PEITC led to further ROS accumulation that caused massive death of cancer cells but no cytotoxicity in normal cells. Importantly, PEITC also significantly prolonged survival in an animal model of human cancer.

"Our study suggests that the intrinsic oxidative stress in cancer cells associated with oncogenic transformation provides a basis for developing therapeutic strategies to preferentially kill cancer cell
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
11-Sep-2006


Page: 1 2

Related biology news :

1. On the cutting edge: Carbon nanotube cutlery
2. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
3. From clinical cancer research: rethinking therapeutic cancer vaccine trials
4. Sensitivity to diverse range of chemotherapeutic drugs linked to common pathway
5. New therapeutic insight into duchenne muscular dystrophy
6. Small molecule derived from Rb2/p130 could act as cancer therapeutic
7. Sphingolipids with therapeutic ends
8. New therapeutic target for Alzheimers could lead to drugs without side effects
9. VBI research offers potential route to diabetes therapeutics
10. Quiet revolution may herald new RNA therapeutics
11. Scientists discover two-component lantibiotic with therapeutic potential

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... an innovation leader in attendance control systems is proud to announce the introduction of ... make sure the right employees are actually signing in, and to even control the ... ... ... ...
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... , June 23, 2016 On Wednesday, ... at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged ... closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on ... ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals ... (NASDAQ: BIND ). Learn more about these stocks ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
Cached News: